Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Brentuximab vedotin

Geo Regions

Important Notice Regarding the Scientific Information You Have Requested

You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven. 

Please acknowledge that you understand this before proceeding.

Brentuximab vedotin

Share to an HCP

Overview + Rationale

  • Brentuximab vedotin (BV) is an antibody-drug conjugate composed of the antibody SGN-30, directed to human CD30,1,2 which is covalently attached to the microtubule-disrupting agent MMAE2,3 via a protease-cleavable mc-vc linker2-4
  • CD30 is expressed in many B- and T-cell lymphomas while having limited expression in normal tissue1
  • Targeted delivery of MMAE to CD30-expressing tumor cells is the primary mechanism of action of brentuximab vedotin.5 However, the direct cytotoxicity associated with brentuximab vedotin may be complemented by secondary effects,6 including the bystander effect and several important immune-oncology related effects, such as immunogenic cell death7,8,9 and antibody-dependent cellular phagocytosis.10

 

Partner: Takeda Pharmaceutical Company Limited.

Mechanism of Action

Stage of Development

Brentuximab vedotin is being investigated in combination with other agent(s) in the tumor types shown here. Safety and efficacy for the uses listed below has not been established.

small icon representing Hematologic Cancer

Peripheral T-Cell Lymphoma (PTCL)

Phase 2 Combination*
small icon representing Hematologic cancer

Diffuse Large B-cell Lymphoma (DLBCL)

Phase 3 Combination*
small icon representing melanoma

Melanoma

Phase 2 Combination*
small icon representing thoracic cancer

Metastatic Non-Small Cell Lung Cancer (NSCLC)*

Phase 2 Combination*
small icon to represent other tumors in blue

Squamous Cell Carcinoma of Head and Neck (SCCHN)*

Phase 2 Combination*
This information is current as of August 5th 2025.

* Closed to Enrollment

REFERENCES:  1. Wahl AF. Cancer Res. 2002: 3736-42; 2. Francisco JA. Blood. 2003: 1458-65; 3. Doronina SO. Nat Biotechnol. 2003: 778-84; 4. Okeley NM. Clin Cancer Res. 2010: 888-97; 5. ADCETRIS prescribing information. June 2023; 6. Li F. Cancer Res. 2016: 2710-19; 7. Gardai SJ. Cancer Res. 2015: Abstract 2469; 8. Muller P. Cancer Immunol Res. 2014: 741-55; 9. Heiser R. Molec Cancer Ther. 2023: doi:10.1158/1535-7163.MCT-23-0118; 10. Oflazoglu E. Blood. 2007: 4370-2. 11. NCT02927769 https://clinicaltrials.gov/study/NCT02927769; 12. NCT04569032. https://clinicaltrials.gov/ct2/show/NCT04569032; 13. NCT04404283. https://clinicaltrials.gov/ct2/show/NCT04404283; 14. NCT04609566. https://clinicaltrials.gov/ct2/show/NCT04609566  Accessed July 7, 2025.